Metabolic syndrome associated with increased risk of endometrial cancer
the ONA take:
Past research has indicated that metabolic syndrome increased older women’s the risk of endometrial cancer, the most common cancer of the female reproductive organs. However, whether the association was due to obesity or metabolic syndrome was unclear.
A new study from the National Institutes of Health demonstrated that metabolic syndrome is associated with increased risk of endometrial cancer. Metabolic syndrome is a cluster of factors that increase a person’s risk of cardiovascular disease, stroke, diabetes, and other metabolic-related diseases.
Using the SEER-Medicare Linked Database, the researchers reviewed information from 16,323 women ages 65 years and older with endometrial cancer diagnosed between 1993 and 2007, along with 100,751 women who did not have the disease.
A diagnosis of metabolic syndrome was determined using criteria set by either the US National Cholesterol Education Program Adult Treatment Panel III (ATP III) or the International Diabetes Foundation.
The researchers found women with metabolic syndrome as determined by the ATP III criteria were 39% more likely to develop endometrial cancer, and those with metabolic syndrome as determined by International Diabetes Foundation criteria were 109% more likely to develop endometrial cancer. After accounting for overweight or obesity among the women, the risk of developing endometrial cancer were 21% higher and 17% higher, respectively.
In addition, excessive weight, hypertension, high triglycerides, and impaired fasting glucose—all factors in metabolic syndrome—increased women’s risk of developing endometrial cancer individually.
Whether the association with endometrial cancer was due to obesity or metabolic syndrome was unclear.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Definitive IMRT Associated With Shorter Feeding Tube Placement Duration in HNC
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|